eBioscience acquires Bender MedSystems' immunoassay technology
29 October 2009
eBioscience Corporation has acquired privately held Austrian immunoassay technology pioneer Bender MedSystems GmbH in an all cash transaction.
The acquisition will provide eBioscience with over 1,000 high profile immunology and oncology products, including the Instant ELISA and FlowCytomix brands that target the life sciences and diagnostics markets.
"Bender MedSystems provides us with a cutting-edge technology platform that, when combined with many of eBioscience's leading cell analysis research and diagnostic products, will facilitate the accelerated development and commercialization of breakthrough innovations," explained eBioscience CEO, Todd R. Nelson Ph.D.
"Bender MedSystems proprietary Instant ELISA technology and associated product lines confer several major competitive advantages over existing technologies including increased sensitivity, significantly simplified handling and reduced analysis time," added Michael Schaude Ph.D., CEO of Bender MedSystems.
Bender MedSystems' novel bead based multiplexing technology and products, marketed and sold under the FlowCytomix brand, allow researchers to analyze simultaneously up to 20 proteins in a single reaction. This highly scalable technology platform can be combined with many of eBioscience's existing technologies that the company intends to use in the development of a significant number of expanded sets of cell analysis product lines.
"The FlowCytomix reagents are designed to run on existing flow cytometry instruments, allowing eBioscience to take full advantage of our current commercial channel without having to invest into an instrument platform. Accordingly, the technology represents an exceptional opportunity for us to increase our presence within the multiplexing segment of the immunoassay market," Dr. Nelson commented.
The Bender MedSystems' acquisition builds on eBioscience's recent expansion in Europe and is complementary to the company's NatuTec operations in Germany. In addition to providing eBioscience with a first class centre of excellence for the development of immunoassays in Europe, the company will now have manufacturing, enhanced customer service, technical support and increased regional distribution capabilities.
Bender MedSystems will serve as eBioscience's European headquarters and will greatly enhance the ability to get products to customers more rapidly and reliably," added Dr. Nelson.
"Bender MedSystems has built an impressive business over the past 11 years and has amassed a quality brand, several highly scalable enabling technologies and value-added product lines and it will be a pleasure to add them to the eBioscience family of companies," Nelson commented.